Ether

Ether

SCHEMBL19971727

CCCCCCCC/C=C\CCCCCCCC(=O)O[C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO.CCOCC

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.54
PRKCE Q02156 1/20 0.54
PRKCQ Q04759 1/20 0.54
PRKCD Q05655 1/20 0.54
DGKA P23743 1/20 0.53
FAAH O00519 3/20 0.51
MAPT P10636 2/20 0.51
CNR2 P34972 2/20 0.51
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51
CNR1 P21554 1/20 0.51
S1PR1 P21453 1/20 0.47
DEGS1 O15121 1/20 0.47
MAPK1 P28482 1/20 0.47
LPAR1 Q92633 5/20 0.46
ENPP2 Q13822 2/20 0.46
LPAR4 Q99677 2/20 0.46
LPAR5 Q9H1C0 2/20 0.46
LPAR2 Q9HBW0 2/20 0.46
LPAR3 Q9UBY5 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL709550 0.95 PRKCA (0.59) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL714739 0.95 PRKCA (0.59) PRKCAPRKCEPRKCQPRKCDDGKA
Oxirane SCHEMBL11211813 0.89 DGKA (0.55) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL714245 0.87 MAPT (0.60) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL715876 0.87 MAPT (0.60) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL3250346 0.87 MAPT (0.60) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL6332412 0.84 PRKCA (0.56) PRKCAPRKCEPRKCQPRKCDDGKA
Ethylene SCHEMBL21633977 0.84 MAPT (0.57) PRKCAPRKCEPRKCQPRKCDDGKA
Ethylene SCHEMBL7947908 0.84 MAPT (0.57) PRKCAPRKCEPRKCQPRKCDDGKA
SCHEMBL23781814 0.83 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDDGKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3871501-B1 MANUFACTURING METHOD FOR THIOCYCLAM HYDROCHLORIDE ARYSTA LIFESCIENCE NORTH AMERICA LLC (US) 2023-03-08 EP claimed
EP-3518673-A1 MANUFACTURING METHOD FOR AND INSECTICIDAL COMPOSITIONS COMPRISING THIOCYCLAM HYDROCHLORIDE Arysta Lifescience North America LLC (US) 2019-08-07 EP claimed
US-20180079739-A1 Manufacturing Method For and Insecticidal Compositions Comprising Thiocyclam Hydrochloride ARYSTA LIFESCIENCE NORTH AMERICA, LLC. 2018-03-22 US claimed
WO-2018053062-A1 MANUFACTURING METHOD FOR AND INSECTICIDAL COMPOSITIONS COMPRISING THIOCYCLAM HYDROCHLORIDE ARYSTA LIFESCIENCE NORTH AMERICA, LLC (US) 2018-03-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079739-A1 Manufacturing Method For and Insecticidal Compositions Comprising Thiocyclam Hydrochloride MTAP, PTMA, TMT1A PRKCA 155/4885PRKCE 205/4885PRKCQ 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.